Men in the lower third of muscular strength had higher rates of mortality than those in the middle or upper thirds. A study of over 3,000 women with breast cancer found that low muscle mass and quality were associated with higher mortality. Older age is a major risk factor for poor outcomes from influenza, COVID-19, and critical illness due to the impacts of aging on muscle loss and frailty. Fortetropin has been shown to increase muscle mass and strength in humans and prevent disuse muscle atrophy in dogs after surgery.

1. ADVANCED NUTRITION FOR MUSCLE HEALTH
Neerav D. Padliya, Ph.D.
Vice President, Research & Development
MYOS RENS Technology, Cedar Knolls, NJ
March 31, 2020 Genetic Edge Compounds

2. WHY DOES MUSCLE HEALTH MATTER?
Longevity
Karolinska Institute Study: Muscle Mass and Mortality [1].
Harvard Study: Muscle Mass and Breast Cancer Survival [2].
Quality of Life
Golfing, Tennis, Dancing or Biking.
Bone Health
Muscle-Bone Biochemical Crosstalk [3].
Muscle-Bone Biomechanical Interactions [4].
Energy Metabolism
Reduced Muscle Mass and Type 2 Diabetes Risk [5].
Avoiding Injury
Muscle Loss, Compromised Balance and Falls [6].
4. Qin, Y. X., et al. Journal of musculoskeletal & neuronal interactions 10.1 (2010): 12.
5. Landi, F., et al. Journal of the American Medical Directors Association 14.8 (2013): 540-541.
6. Landi, F., et al. Clinical nutrition 31.5 (2012): 652-658.
1. Ruiz, J. R., et al. Bmj 337 (2008): a439.
2. Caan, Bette J., et al. JAMA oncology 4.6 (2018): 798-804.
3. Hamrick, M. W. BoneKEy reports 1 (2012).
Genetic Edge Compounds

3. MUSCLE MASS & LONGEVITY
Karolinska Institute Study – Muscular Strength & Mortality in Men:
• Examine Association Between Muscular Strength and Mortality From All Causes,
Cardiovascular Disease and Cancer in Men.
• Prospective Cohort Study (8762 men, aged 20-80).
• Aerobics Center Longitudinal Study (Cooper Clinic, Dallas, TX).
• Average Follow-up Period: 18.9 years.
• Outcome Measures
• All Cause Mortality Up To Dec. 31, 2003.
• Muscular Strength (One Repetition Maximal Measures for Leg and Bench Presses).
Ruiz, Jonatan R., et al. "Association between muscular strength and mortality in men: prospective cohort study." Bmj 337 (2008): a439.
Genetic Edge Compounds

4. MUSCLE MASS & LONGEVITY
Karolinska Institute Study – Muscular Strength & Mortality in Men:
Ruiz, Jonatan R., et al. "Association between muscular strength and mortality in men: prospective cohort study." Bmj 337 (2008): a439.
Men in the lower third of
muscular strength had
increased rates of mortality
from all causes, cardiovascular
disease and cancer compared
to men in the middle and
upper thirds of muscular
strength.
Genetic Edge Compounds

5. COVID-19: OLDER ADULTS ARE MOST IMPACTED
Riou J, Hauser A, Counotte MJ, Althaus CL. Adjusted age-specific case fatality ratio during the COVID-19 epidemic in Hubei, China, January and February 2020. medRxiv. 2020 Jan 1.
Covid-19 Deaths in Italy
Genetic Edge Compounds

6. INFLUENZA: OLDER ADULTS ARE MOST IMPACTED
Riou J, Hauser A, Counotte MJ, Althaus CL. Adjusted age-specific case fatality ratio during the COVID-19 epidemic in Hubei, China, January and February 2020. medRxiv. 2020 Jan 1.
Symptomatic Illnesses Medical Visits Hospitalizations Deaths
Age group Estimate 95% UI Estimate 95% UI Estimate 95% UI Estimate 95%UI
0-4 yrs 3,633,104
(2,506,551,
7,199,330)
2,434,180
(1,667,892,
4,820,252)
25,328
(17,475,
50,191)
266 (85, 713)
5-17 yrs 7,663,310
(6,027,982,
10,438,419)
3,984,921
(3,067,414,
5,415,715)
21,012
(16,528,
28,621)
211 (38, 640)
18-49 yrs 11,913,203
(10,077,523,
16,032,899)
4,407,885
(3,498,694,
6,064,550)
66,869
(56,565,
89,993)
2,450 (1,402, 5,813)
50-64 yrs 9,238,038
(6,582,690,
15,759,286)
3,972,356
(2,712,868,
6,886,487)
97,967
(69,808,
167,123)
5,676 (3,547, 13,486)
65+ yrs 3,073,227
(2,008,898,
6,030,701)
1,721,007
(1,097,482,
3,394,980)
279,384
(182,627,
548,246)
25,555
(17,874,
41,363)
All ages 35,520,883
(31,323,881,
44,995,691)
16,520,350
(14,322,767,
21,203,231)
490,561
(387,283,
766,472)
34,157
(26,339,
52,664)
Genetic Edge Compounds

7. AGING IMPACTS INFLUENZA-RELATED MUSCLE LOSS
On influenza-induced muscle inflammation,
atrophy and functional impairment:
“We have demonstrated that key inflammatory
signals, and key ubiquitin proteasome
components, both atrogin1 and MuRF1, as
well as ubiquitin B and ubiquitin C, are
upregulated. As it is known that muscle repair
is diminished with aging, it is likely these
muscle losses are not easily recoverable.”
Bartley JM, Pan SJ, Keilich SR, Hopkins JW, Al-Naggar IM, Kuchel GA, Haynes L. Aging augments the impact of influenza respiratory tract infection on mobility impairments, muscle-
localized inflammation, and muscle atrophy. Aging (Albany NY). 2016 Apr;8(4):620.
Genetic Edge Compounds

8. SARCOPENIA & ICU SURVIVAL: VENTILATOR WEANING
Likou Chang Gung Memorial Hospital, Taiwan:
• Sarcopenia may impair the respiratory musculature, which can subsequently influence the
outcome of ventilator weaning.
• 96 patients undergoing mechanical ventilation in the surgical intensive care unit (ICU) were
enrolled.
• Demographic data and weaning parameters were recorded from the prospectively collected
database, and the total psoas muscle area (TPA) was determined at the level of the 3rd lumbar
vertebra by Computed Tomography (CT).
• Receiver operating characteristic (ROC) curve analysis was conducted to investigate the
predictive capability of TPA and weaning parameters for predicting weaning outcomes.
Kou HW, Yeh CH, Tsai HI, Hsu CC, Hsieh YC, Chen WT, Cheng HT, Yu MC, Lee CW. Sarcopenia is an effective predictor of difficult-to-wean and mortality among critically ill surgical patients. PloS one.
2019;14(8).
Genetic Edge Compounds

9. SARCOPENIA & SURVIVAL: CRITICALLY ILL SURGICAL PATIENTS
Likou Chang Gung Memorial Hospital, Taiwan:
Kou HW, Yeh CH, Tsai HI, Hsu CC, Hsieh YC, Chen WT, Cheng HT, Yu MC, Lee CW. Sarcopenia is an effective predictor of difficult-to-wean and mortality among critically ill surgical patients. PloS one.
2019;14(8).
Sarcopenia (p = 0.038) and APACHE II score
(p<0.001) were found to be independent predictors for
DtW, whereas RR<30 breaths/min (p = 0.044), RSBI
<105 (p = 0.045), and Vt >5 ml/kg (p = 0.004) were
shown to significantly decrease the odds of DtW. On
the other hand, sarcopenia (p = 0.042), emergent
operation (p = 0.033), and SOFA score (p = 0.004)
were independent risk factors for ICU mortality.
Genetic Edge Compounds

10. MUSCLE MASS & BREAST CANCER SURVIVAL
Harvard / Brigham & Women’s Hospital Study – Non-Metastatic Breast Cancer:
• Are sarcopenia, poor muscle quality, and excess adiposity at diagnosis associated with overall
mortality in patients with nonmetastatic breast cancer?
• Observational Study of 3241 women with non-metastatic breast cancer (Jan. 2000 – Dec. 2013).
• Computed tomography (CT) performed at time of diagnosis.
 Sarcopenia (Low Muscle Mass), Poor Muscle Quality (Low Muscle Radiodensity) or Excess
Adiposity.
• Main Outcome Measures
 Overall Survival Time and All Cause Mortality.
Caan, Bette J., et al. "Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer." JAMA oncology 4.6 (2018): 798-804.
Genetic Edge Compounds

11. MUSCLE MASS & BREAST CANCER SURVIVAL
Harvard / Brigham & Women’s Hospital Study – Non-Metastatic Breast Cancer:
Caan, Bette J., et al. "Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer." JAMA oncology 4.6 (2018): 798-804.
Genetic Edge Compounds

12. WHAT IS FRAILTY?
Clinical Definition of Frailty:
Presence of three or more of the following
components:
1. Shrinking
2. Weakness
3. Poor endurance and energy
4. Slowness
5. Low physical activity level
Fried, Linda P., et al. "Frailty in older adults: evidence for a phenotype." The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56.3 (2001): M146-M157.
Genetic Edge Compounds

13. FRAILTY & SARCOPENIA
“This editorial has suggested that sarcopenia
is the major cause of frailty. Frailty can be
screened for by general practitioners as
demonstrated by the Gerontopole Frailty
Screening Tool 54, 55. A simple screening tool,
the FRAIL, takes less than 15 s to do and does
not require a physician to administer it.
Treatments for frailty clearly exist. For these
reasons we suggest that it is time to couple
sarcopenia and frailty and increase its
community awareness.”
Morley, John E., et al. "From sarcopenia to frailty: a road less traveled." Journal of cachexia, sarcopenia and muscle 5.1 (2014): 5-8.
Genetic Edge Compounds

14. FORTETROPIN®
• Natural bioactive composition made from fertilized chicken egg yolks.
• Patented low-temperature manufacturing process developed by German Institute of Food Technology/DIL to
retain activity of biomolecules.
• Increases muscle mass and strength [1], prevents atrophy [2], and improves recovery [2].
• Manufactured in modern, state-of-the-art GMP facilities.
• Issued United States patents:
⚬ 8,815,320
⚬ 10,165,785
1. Sharp, Matthew H., et al. Journal of the American College of Nutrition 35.8 (2016): 679-691.
2. White, Dana A., et al. "Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau
leveling osteotomy." Plos one 15.4 (2020): e0231306.
Genetic Edge Compounds

15. EGG INTAKE, CVD RISK & MORTALITY
Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G. Association of egg intake with blood lipids,
cardiovascular disease, and mortality in 177,000 people in 50 countries. The American Journal of Clinical Nutrition. 2020 Jan 21.
“In 3 large international prospective studies
including ∼177,000 individuals, 12,701
deaths, and 13,658 CVD events from 50
countries in 6 continents, we did not find
significant associations between egg intake
and blood lipids, mortality, or major CVD
events. The ONTARGET and TRANSCEND
trials were registered at clinicaltrials.gov as
NCT00153101. The PURE trial was registered
at clinicaltrials.gov as NCT03225586.”
Genetic Edge Compounds

16. GEC IMMORTAL®
POWERED BY FORTETROPIN®
Genetic Edge Compounds

17. IMPACT OF FORTETROPIN® ON OLDER ADULTS
 Impact of Fortetropin® on the rate of muscle
protein synthesis after 21 days of
intervention was studied in clinical trial [1].
 20 subjects (10 men and 10 women).
 Ages (60 – 75 years old).
 Randomized, Double-Blind, Placebo
Controlled Study Design:
o 10 subjects received Fortetropin®.
o 10 subjects received placebo (cheese
powder).
Evans, William J., Presentation at International Conference on Frailty & Sarcopenia Research, Toulouse, France, March 11, 2020.

18. Mitochondrial Biogenesis, Cellular
Respiration, Oxidative Stress
• Calorie Restriction
• Exercise
• Anabolic Treatment
Nuclear Proteins (Histones)
• Muscle Regeneration and Repair
• Anabolic Treatment
Cytosolic Proteins
• Glycolysis / Gluconeogenesis
• TCA Cycle
• Cell Energetics
• Cytoplasmic Vesicles
• Ion Transport
• Intracellular Signaling
• Stress Response
Extracellular Matrix Proteins
• Muscle Damage
• Regeneration and Repair
Myofibril, Z-band, Contractile Proteins
• Muscle Damage and Atrophy
• Muscle Regeneration and Repair
• Exercise
• Anabolic Treatment
Sarcoplasmic
Reticulum
Proteins
Anabolic treatment
Exercise
Muscle Damage
Repair
Muscular Dystrophy
• Dystrophin
• Collagen VI, Laminin
• Signaling Proteins
PROTEOME DYNAMICS IN SKELETAL MUSCLE
Evans, William J.,
Presentation at
International
Conference on Frailty
& Sarcopenia
Research, Toulouse,
France, March 11,
2020.
Genetic Edge Compounds

19. FRACTIONAL SYNTHESIS OF 38 MYOFIBRIL PROTEINS
Evans, William J.,
Presentation at
International
Conference on Frailty &
Sarcopenia Research,
Toulouse, France,
March 11, 2020.
IN CONTROL AND FORTETROPIN® GROUPS
Overall magnitude
of increase was
~15% in
Fortetropin-
supplemented
group.

20. IMPACT OF FORTETROPIN® ON MUSCLE GAIN
55.
56.
57.
58.
59.
60.
61.
Placebo 6.6 g 19.8 g
Pre Post
Lean Body Mass (kg)
4.5
4.73
4.95
5.18
5.4
5.63
Placebo 6.6 g 19.8 g
Pre Post
Muscle Thickness (cm)
*
*
*
*
* p < 0.05
• Double blind, placebo controlled, randomized, 12 week study
of Fortetropin® in males (18-21 yrs).
• Monitored and supervised resistance training 2x per week;
dietician-recommended and monitored diet.
• 45 males randomized in 3 arms; age range of 19.7 + 1.5 years; weight
range of 70.6 + 10.4 kg.
• Primary Endpoints: skeletal muscle hypertrophy and lean body mass.
1. Sharp, Matthew H., et al. "The
Effects of Fortetropin
Supplementation on Body
Composition, Strength, and Power
in Humans and Mechanism of
Action in a Rodent Model." Journal
of the American College of
Nutrition 35.8 (2016): 679-691.
Genetic Edge Compounds

21. PRECLINICAL STUDY: TPLO SURGERY RECOVERY
• TPLO surgery is performed to repair tears of CCL.
• Operated limb must be immobilized for several weeks after surgery resulting in significant muscle
loss.
• Following TPLO surgery [1]:
o 50 dogs received Fortetropin® on a daily basis.
o 50 dogs received a macronutrient-matched placebo (cheese powder).
• Evaluations at t = 0, 8 and 12 weeks
o Thigh Circumference, Muscle Thickness, Stance Analysis, Blood Chemistry.
• Key Conclusions:
o Fortetropin® prevented muscle loss in affected and unaffected limbs.
o Fortetropin®-supplemented dogs had greater improvement in weight bearing capacity on
operated limb.
o Fortetropin® supplementation prevented a rise in levels of myostatin.
1. White, Dana., et al. PLOS One (2020), Revised manuscript submitted.

22. RECOVERY FROM TPLO SURGERY: RESULTS
Time, t
(weeks)
Fortetropin®
Supplemented
Affected
Limb
Fortetropin®
Supplemented
Unaffected
Limb
Placebo
Supplemented
Affected
Limb
Placebo
Supplemented
Unaffected
Limb
Fortetropin®
Supplemented
Affected
Limb
Placebo
Supplemented
Affected
Limb
t = 0 34.24 36.51 33.74 36.30 8.00% 9.63%
t = 8 33.70 35.80 32.53 34.26 13.74% 12.88%
Thigh Circumference (cm) Weight Bearing Capacity (%)
White, Dana A., et al. "Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy." Plos one 15.4 (2020): e0231306.

23. IMPACT OF FORTETROPIN® ON MUSCLE DISUSE ATROPHY
• Unilateral leg immobilization
model – wearing a cast/knee
brace on single leg for 2 weeks
induces muscle disuse atrophy.
• Does Fortetropin® reduce muscle
disuse atrophy relative to
placebo?
• Randomized, double-blind,
placebo-controlled human clinical
study.
• Two parallel groups: Placebo
(n=12) and Fortetropin® (n=12).
• Young male subjects.
Principal Investigator: Stuart Phillips, PhD.
Current Status: Patient recruitment
underway (January 2020).
Genetic Edge Compounds

24. PATIENT DEMOGRAPHICS
Patient Population Clinical Evidence
Sports Nutrition Sharp, M.H., Lowery, R.P., Mobley, C.B., Fox, C.D., de Souza, E.O., Shields,
K.A., Healy, J.C., Arick, N.Q., Thompson, R.M., Roberts, M.D. and Wilson,
J.M., 2016. The effects of Fortetropin® supplementation on body
composition, strength, and power in humans and mechanism of action in
a rodent model. Journal of the American College of Nutrition, 35(8),
pp.679-691.
Healthy Aging Evans, W. J., Shankaran, M., Nyangau, E., Field, T., Mohammed, H., Wolfe,
R., Schutzler, S., Hellerstein, M. Effects of Fortetropin® on the rate of
muscle protein synthesis in older men and women: a randomized,
double-blinded control study. Oral presentation at International
Conference on Frailty & Sarcopenia Research, Toulouse, France, March
11, 2020.
Recovery and
Rehabilitation
White, Dana A., et al. "Fortetropin inhibits disuse muscle atrophy in dogs
after tibial plateau leveling osteotomy." Plos one 15.4 (2020): e0231306.
Phillips, S.M. et al. The impact of Fortetropin on muscle atrophy in
young men during periods of muscle disuse. *Human Clinical Trial
Underway.
Genetic Edge Compounds

25. TESTIMONIALS
“Fortetropin® clearly has a robust effect on the rate of muscle protein synthesis in older adults. It is rare for a nutrition product to show such a
consistent and positive effect.” --- William J. Evans, Ph.D., Adjunct Professor of Nutrition, University of California, Berkeley
“Very few nutrition products have been studied to this degree.” --- Stuart Phillips, Ph.D., Professor of Kinesiology & Tier 1 Canada Research
Chair, McMaster University, Canada
“I took Fortetropin® while doing the same workouts that I was doing before. It helped me gain about 15 pounds of muscle in a year and a
half.” --- Karl Nelson, Former NFL Offensive Tackle, New York Giants, Super Bowl Champ and Cancer Survivor.
“This will make your protein supplements better and your 8-pack harder! It tastes great, like the malted part of a milkshake – it’s
delicious, we love it!” --- Joe Thomas, Former NFL Offensive Tackle, Cleveland Browns.
“This is a special product that can help any athlete reach new heights. I am impressed by the depth of clinical research behind the product
and it’s potential to unlock new levels of performance for all athletes.” --- Aaron Gordon, NBA Superstar, Orlando Magic.
“I’m proud to represent a brand that is committed to delivering cutting edge products made with safe, all-natural ingredients that help
improve strength, speed and recovery.” --- Carli Lloyd, FIFA World Champion and Olympic Gold Medalist.
Genetic Edge Compounds

26. REVOLUTIONARY, ADVANCED
• Fortetropin® is an all natural, highly safe
nutrition product that can enable patients to
gain muscle mass.
• In human clinical trials, Fortetropin® has been
shown to increase the rate of muscle protein
synthesis and increase lean muscle mass.
• Gaining muscle mass will enable patients to
enjoy an active and healthy lifestyle.
NUTRITON FOR MUSCLE HEALTH
Extensive clinical research has shown the
relationship between muscle health and longevity.
Genetic Edge Compounds